Natera, Inc. (NTRA)
Nasdaq: NTRA · Services-Medical Laboratories · Austin, TX · filing with the SEC since 2014
Grade6.6
◀ Past 5.8● Present 6.5▶ Future 7.5
Who owns Natera, Inc.
As filed with the SECHolders of 5% or more
4
JPMorgan Chase & Co. holds 9.1% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Jan 23, 2026 says.
Directors and officers
16
report now, of 21 people on the record since 2010. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
JPMorgan Chase & Co.
SCHEDULE 13G/A · filed Jan 23, 2026 · Common Stock, par value $0.0001 per share · 7.7% in Jul 22, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · COMMON STOCK · 7.8% in Feb 17, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What NTRA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Foresight Diagnostics, Inc.
A company bought · acquisition · owns, named in the 10-K filed Feb 27, 2026
Insider tradesForm 4
538sales
0purchases
510sales on a scheduled plan
12people selling
$365Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 32 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN | 110 | $135M | 110 | 0 | $0 |
| Chapman Steven Leonard | CEO AND PRESIDENT | 53 | $61.1M | 53 | 0 | $0 |
| Botha Roelof | director | 17 | $34.9M | 0 | 0 | $0 |
| Sheena Jonathan | CO-FOUNDER | 167 | $30.7M | 167 | 0 | $0 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | 72 | $24.9M | 71 | 0 | $0 |
| Rabinowitz Daniel | SEC. AND CHIEF LEGAL OFFICER | 42 | $24.0M | 42 | 0 | $0 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | 36 | $22.7M | 36 | 0 | $0 |
| Rosenman Herm | Chief Financial Officer | 5 | $15.1M | 1 | 0 | $0 |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER | 19 | $9.8M | 19 | 0 | $0 |
| Baynes Roy D. | director | 8 | $2.8M | 8 | 0 | $0 |
| Marcus Gail Boxer | director | 4 | $2.4M | 0 | 0 | $0 |
| Chapman Rowan E | director | 5 | $1.8M | 3 | 0 | $0 |